This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Expanding Diabetes Business Supports ABT Stock, FX Issues Stay
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
BIO Stock Might Rise Following the Offer to Acquire Stilla
by Zacks Equity Research
Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.
ZBH Stock Hurt by Margin Concerns and Difficult Solvency
by Zacks Equity Research
Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations.
ALGN Stock Gains on the Launch of Invisalign Palatal Expander in Turkey
by Zacks Equity Research
Align Technology commercially launches its Invisalign Palatal Expander System in Turkey after approval from TMMDA.
EMEA Expansion to Support BSX Stock Amid Fierce Competition
by Zacks Equity Research
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
Wall Street Analysts Think Omnicell (OMCL) Could Surge 29.03%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 29% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MYGN Stock Might Rise on Collaboration With CancerCARE
by Zacks Equity Research
Myriad Genetics entered into an agreement with CancerCARE for Life to provide individuals within the latter's network with access to the MyRisk Hereditary Cancer Test.
Omnicell Q4 Earnings & Revenues Beat, Stock Up, Gross Margin Rises
by Zacks Equity Research
OMCL returns to year-over-year revenue growth in the fourth quarter of 2024.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Omnicell (OMCL) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 5.26% and 3.35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
STXS Stock Gains Following the First Order for its GenesisX
by Zacks Equity Research
Stereotaxis receives its first order for the next-generation robotic system, GenesisX. The company expects a full commercial launch in the coming months.
Inspire Medical Systems (INSP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Omnicell Stock a Solid Pick for Your Portfolio Right Now?
by Zacks Equity Research
OMCL stays on investors' radar due to the strong performance of the Advanced Services portfolio.
Omnicell (OMCL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add PODD Stock to Your Portfolio Now
by Zacks Equity Research
Insulet stays on investors' radar owing to its solid progress with Omnipod 5 and strong solvency position.
CLPT Stock Gains on FDA Clearance for Navigation Software Version 3.0
by Zacks Equity Research
ClearPoint achieves FDA 510(k) clearance for its Navigation Software Version 3.0, designed to standardize cell and gene therapy delivery in the United States.
Reasons to Retain ABT Stock in Your Portfolio Now
by Zacks Equity Research
Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.
Expanding EPD Business Supports ABT Stock Amid Macro Issues
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
MYGN Stock Gains Following the Launch of Know More Sooner
by Zacks Equity Research
Myriad Genetics launches an online prenatal genetic testing resource, the Know More Sooner website, to provide comprehensive information about reproductive and prenatal genetic testing.
Zacks Industry Outlook Enovis, Omnicell and Phreesia
by Zacks Equity Research
Enovis, Omnicell and Phreesia have been highlighted in this Industry Outlook article.
3 Medical Info Systems Stocks to Buy as Stargate AI Drives Industry Prospects
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Enovis, Omnicell and Phreesia are expected to gain from the GenAI wave.
The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC
by Zacks Equity Research
Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog.
4 MedTech Stocks Poised to Thrive Under Second Trump Presidency
by Urmimala Biswas
Four MedTech stocks that are set to benefit from Trump 2.0 are DOCS, OMCL, EMBC and COR.
Emerging Market Expansion Supports ZBH Stock Amid Macro Issues
by Zacks Equity Research
Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges.